UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
34.54
+0.16 (0.47%)
At close: Jun 26, 2026, 4:00 PM EDT
34.10
-0.44 (-1.27%)
After-hours: Jun 26, 2026, 7:02 PM EDT
UroGen Pharma Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for UroGen Pharma stock have an average target of 36.63, with a low estimate of 18 and a high estimate of 45. The average target predicts an increase of 6.05% from the current stock price of 34.54.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Buy Maintains $35 | Buy | Maintains | $35 | +1.33% | Jun 16, 2026 |
Unknown Analyst Guggenheim No rating | Guggenheim | Buy Maintains $32 | Buy | Maintains | $32 | -7.35% | Jun 3, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $45 | Buy | Reiterates | $45 | +30.28% | Jun 3, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $40 | Buy | Reiterates | $40 | +15.81% | May 19, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $18 | Hold | Maintains | $18 | -47.89% | May 18, 2026 |
Financial Forecast
Revenue This Year
265.94M
from 109.79M
Increased by 142.23%
Revenue Next Year
419.77M
from 265.94M
Increased by 57.84%
EPS This Year
-0.91
from -3.19
EPS Next Year
1.23
from -0.91
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 303.5M | 514.6M | |
| Avg | 265.9M | 419.8M | |
| Low | 241.1M | 363.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 176.4% | 93.5% | |
| Avg | 142.2% | 57.8% | |
| Low | 119.6% | 36.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.26 | 2.79 | |
| Avg | -0.91 | 1.23 | |
| Low | -1.70 | 0.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.